AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 92 min read

TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO

TRex Bio filed for a Nasdaq IPO, offering 8,333,334 shares at $14.00 each, aiming to raise $116.7 million. The company, focused on immunoregulatory medicines, plans to use proceeds for clinical trials and general corporate purposes. Eli Lilly has shown interest in purchasing shares. TRex Bio's lead candidate, TRB-061, is in Phase 1b trials for atopic dermatitis, with data expected in mid-2027.

Original reporting
tradingview.com
Published Oct 9, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TRex Bio, Clinical-Stage Immunology Biopharma, Files for Nasdaq Global Select Market IPO — source image
Source · tradingview.com
Decision brief

The 30-second read

High
01

Why it matters

The IPO filing provides fresh capital to advance Phase 1/2 trials, potentially de‑risking the pipeline and attracting further investment.

02

Market read

First disclosure of a $116M biotech IPO on Nasdaq, creating immediate trading interest and sector visibility.

03

What to watch

Potential dilution from the over‑allotment option and reliance on a single lead candidate could temper enthusiasm.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

TRex Bio is a clinical‑stage company developing Treg‑modulating immunotherapies, with collaborations with Eli Lilly.

Market effects

Sector

Adds a new player to the clinical‑stage immunology biotech space, may boost sector interest in Treg‑targeted therapies.

Regional

Minor impact on US biotech listings; no broader regional effect.

Global

Limited to investors tracking biotech IPO pipelines.

Counterpoint

What could challenge this read

If the IPO pricing is too optimistic, the stock could face immediate post‑listing sell‑off.

Key entities

  • company
    TRex Bio

    Clinical‑stage immunology biopharma filing for IPO.

  • partner
    Eli Lilly

    Potential investor holding up to 19.9% post‑offering.

Read at source← All news

StoryTRex Bio prices Nasdaq IPO at $14 per share, raising about $116.7 million

Also covered by

5 outlets

Related articles

OCT 9
HighAI 8/10

TRex Bio raises $116.7 million in IPO priced at $14 a share

TRex Bio Inc. raised $116.7 million in its IPO, priced at $14 per share. J.P. Morgan and Evercore led the offering, indicating institutional confidence. The company focuses on immunology, an area of sustained investor interest. All shares were pre-allocated to institutional buyers, with the first public trading opportunity upcoming.

247wallst.com2 min
OCT 9
HighAI 8/10

TRex Bio IPO raises $116.7 million, prices at bottom of range

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

finance.yahoo.com2 min
OCT 9
HighAI 8/10

TRex Bio prices $117M IPO to support immune drug work

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

finance.yahoo.com2 min
OCT 9
HighAI 9/10

TRex Bio, Inc. Prices $116.7M IPO at $14

TRex Bio priced 8.3M shares at $14 each, raising $116.7M in its IPO. Trading begins Oct. 9 on Nasdaq under ticker TRXB. Underwriters have a 30-day option for 1.25M more shares. The company plans to use proceeds for its clinical-stage immunology pipeline.

tradingview.com1 min